Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$2.06
+1.5%
$2.11
$0.76
$2.73
$76.77M1.39117,164 shs72,291 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.56
+5.3%
$3.78
$1.60
$16.55
$264.38M1.17942,412 shs485,276 shs
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$10.24
-1.3%
$11.24
$9.76
$19.22
$294.79M0.85410,782 shs214,774 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$41.26
+4.6%
$35.42
$5.21
$46.58
$338.01M1.2945,289 shs41,188 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Corporation stock logo
APYX
Apyx Medical
+3.05%-13.62%-9.38%+22.29%+58.59%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-1.17%-11.29%-21.58%+34.66%-77.18%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-0.86%-13.00%-5.56%-14.16%-7.90%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
+7.46%-1.08%+2.98%+36.65%+3,944,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Corporation stock logo
APYX
Apyx Medical
1.269 of 5 stars
0.03.00.04.20.61.70.6
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1.5657 of 5 stars
3.61.00.00.01.90.80.0
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.7376 of 5 stars
3.51.00.00.01.60.80.6
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
0.944 of 5 stars
2.50.00.00.00.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Corporation stock logo
APYX
Apyx Medical
2.67
Moderate BuyN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56252.68% Upside
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$19.6792.06% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
3.00
Buy$49.0018.76% Upside

Current Analyst Ratings Breakdown

Latest APYX, SNWV, CATX, and CLPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/1/2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
7/29/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$49.00
7/12/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$48.10M1.62N/AN/A$0.20 per share10.30
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$31.39M9.27N/AN/A$0.69 per share14.84
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M10.84N/AN/A($1.72) per share-23.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%N/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%11/6/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$8.25N/AN/A-97.03%N/A-135.15%N/A

Latest APYX, SNWV, CATX, and CLPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million
8/8/2025Q2 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million
8/7/2025Q2 2025
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Corporation stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Corporation stock logo
APYX
Apyx Medical
4.61
4.72
3.95
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.46
7.30
6.45
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.43
0.31

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
55.33%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
15.20%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Corporation stock logo
APYX
Apyx Medical
27037.82 million32.07 millionOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.26 million65.21 millionOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11028.43 million26.45 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.57 million7.29 millionN/A

Recent News About These Companies

Sanuwave (SNWV) Q2 Revenue Jumps 42%
Sanuwave Announces Q2 FY2025 Financial Results
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
Sanuwave Announces Q1 FY2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apyx Medical stock logo

Apyx Medical NASDAQ:APYX

$2.06 +0.03 (+1.48%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 -0.06 (-3.11%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.56 +0.18 (+5.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.56 0.00 (0.00%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$10.24 -0.13 (-1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$10.26 +0.02 (+0.20%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$41.26 +1.81 (+4.59%)
As of 04:00 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.